Abstract:NQO2 is an NRH-dependent quinone reductase that catalyzes the two-electron reduction of quinones to their corresponding hydroquinones. Despite structural similarities between NAD(P)H quinone oxidoreductase 1 (NQO1) and NQO2 many compounds have been shown to bind selectively to NQO2. Previous studies have shown that many drugs including resveratrol, quercetin, chloroquine, and imatinib can bind to and inhibit the catalytic activity of NQO2. Whether the binding and inhibition of NQO2 influences the pharmacology of these compounds is currently unknown. In this study we have developed a series of indolequinones as mechanism-based inhibitors of NQO2. These compounds were based on ES936 (5-methoxy-1,2-dimethyl-3-(4-nitrophenoxy)methylindole-4,7-dione) an efficient mechanism-based inhibitor of NQO1. We found that substitution of the 5-methoxy group in ES936 with an aminoalkylamino side chain generated potent mechanism-based inhibitors of NQO2 that do not efficiently inhibit NQO1. Interestingly, MD436 (5-amino-1,2-dimethyl-3-(2,4,6-trifluorophenoxy)methylindole-4,7-dione) a compound that contains only an amino group at the 5-position was a mechanism-based inhibitor of NQO1 and NQO2. Structural requirements for optimal inhibition of NQO2 were examined and found to include an aminoalkylamino side chain at the 5-position. NQO2 inhibition was observed with compounds with alkyl chains that varied from 3 to 8 carbons in length, with maximal inhibition observed with compounds that possessed chain lengths of between 3 to 5 carbons. Compounds where the aminoalkyl chain terminated in either an unsubstituted amino group or a dimethyl substituted amino group were efficient inhibitors of NQO2. Compounds with substitutions at the 6-position were not efficient mechanism-based inhibitors of NQO2 despite molecular docking studies that suggested NQO2 could accommodate either 5 or 6-position aminoalkylamino side chains. Co-crystallization studies are currently underway to more precisely define the physical interactions between compounds substituted at the 5-position and NQO2. As previously observed for a series of NQO1 mechanism-based inhibitors, structural requirements for efficient inhibition of NQO2 also include a methyl group at the 2-position of the indole ring and a substituent at the 3-position capable of leaving to generate a reactive iminium electrophile following enzymatic reduction. MD372 (5-(3-aminopropylamino)-1,2-dimethyl-3-(2,4,6-trifluorophenoxy)methylindole-4,7-dione) was tested for NQO2 inhibition using the human leukemia cell line K562 that has been shown to contain very high levels of NQO2 protein and activity. Treatment of K562 cells with MD372 (100nM) for 15 min resulted in greater than 95% inhibition of NQO2 catalytic activity, confirming that these compounds enter cells and efficiently inhibit NQO2 (Supported by R21 HL095995). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5471.

Characterization of naphthoquinones as inhibitors of glutathione reductase and inducers of intracellular oxidative stress

Characterisation of Naturally Occurring Isothiocyanates As Glutathione Reductase Inhibitors

Characterization of Bioactive Thiophenes from the Dichloromethane Extract of Echinops Grijisii As Michael Addition Acceptors

Abstract 4061: Depleting the cellular level of glutathione and subsequently<i>S</i>-glutathionylation of keap1 by electrophilic agents activates keap1-nrf2 pathway

Abstract 4061: Depleting the cellular level of glutathione and subsequently S -glutathionylation of keap1 by electrophilic agents activates keap1-nrf2 pathway

Dissecting The Role Of Multiple Reductases In Bioactivation And Cytotoxicity Of The Antitumor Agent 2,5-Diaziridinyl-3-(Hydroxymethyl)-6-Methyl-1,4-Benzoquinone (Rh1)

NAD(P)H:quinone Oxidoreductase 1 (NQO1) in the Sensitivity and Resistance to Antitumor Quinones.

Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.

A Small Molecule Targeting Glutathione Activates Nrf2 and Inhibits Cancer Cell Growth Through Promoting Keap-1 S-glutathionylation and Inducing Apoptosis.

NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.

Discovery Of 6-(7-Nitro-2,1,3-Benzoxadiazol-4-Ylthio)Hexanol Derivatives As Glutathione Transferase Inhibitors With Favorable Selectivity And Tolerated Toxicity

Induction of Quinone Reductase NQO1 by Resveratrol in Human K562 Cells Involves the Antioxidant Response Element ARE and is Accompanied by Nuclear Translocation of Transcription Factor Nrf2

Novel NQO1 Substrates Bearing Two Nitrogen Redox Centers: Design, Synthesis, Molecular Dynamics Simulations, and Antitumor Evaluation.

Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy

Advances on Structure-Activity Relationship of NQO1-targeting Antitumor Quinones

Quercetin-Induced Glutathione Depletion Sensitizes Colorectal Cancer Cells to Oxaliplatin

Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells

Synthesis of Naphthazarin Derivatives and Identification of Novel Thioredoxin Reductase Inhibitor As Potential Anticancer Agent

Abstract 2581: Indolequinone Mechanism-Based Inhibitors of Quinone Reductases: Structural Basis for Selective Inhibition of NQO2 Relative to NQO1

Naphthazarin Derivatives (V): Formation of Glutathione Conjugate and Cytotoxic Activity of 2-or 6-Substituted 5,8-Dimethoxy-1,4-napthoquinones in the Presence of Glutathione- S -Transferase, in Rat Liver S-9 Fraction and Mouse Liver Perfusate

Abstract 5471: Mechanism-based inhibition of NRH: quinone oxidoreductase 2 (NQO2) by a series of aminoalkylamino substituted indolequinones